Houman Ashrafian

SV Health Investors LLP (SV Health Investors) is a venture capital firm founded in 1994 by Peter McPartland. The firm is headquartered in London.

SV Health Managers LLP (SVHM) is the investment management subsidiary of SV Life Sciences Advisers LLP in the UK. Established in 2005, the firm was formerly known as SV Life Sciences Managers LLP and changed their name to SV Health Managers LLP in 2017. Based in London, the firm manages the International Biotechnology Trust plc (LSE: IBT), an investment trust vehicle listed on the London Stock Exchange into which corporate and private investors may invest.

Heart Metabolics Ltd. operates as a biopharmaceutical company that engages in developing new treatments for orphan disease including cardio-metabolic diseases. The firm provides drugs to treat heart failure for hypertrophic cardiomyopathy patients. The company was founded by Michael Paul Frenneaux and Houshman Ashrafian in 2004 and is headquartered in Dublin, Ireland.

Part of Envisics LLC, Dualitas Ltd. is a British company that engages in developing technologies to deliver holographic and augmented reality products and services. The company is based in London, UK. The company was founded in 2016 by Houman Ashrafian.

Weatherden Ltd. is a pioneering clinical development consulting group based in London, UK. The British company specializes in scientific strategy, translational medicine, clinical development, diligence preparation, and support for M & A. Weatherden focuses on de-risking programs early and optimizing clinical, regulatory, and commercial pathways to bring life-changing medicines to patients. With over 750 years of combined industry experience, they are dedicated to improving the chances for breakthrough therapies to address unmet clinical needs. The private company, founded by Duncan McHale and Houman Ashrafian, provides trusted advice to biopharma, funds, startups, spin-outs, and nonprofits. Emma Tinsley has been the CEO of the company since 2017.

Imbria Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company developing novel therapies that restore cellular energy deficits. It focuses on restoring or improving the cell?s ability to produce energy where energy imbalances are at the root of disease, including cardiovascular diseases and inborn errors of metabolism. The company was founded by Andrew Levin and David-Alexandre C. Gros in 2018 and is headquartered in Boston, MA.

Sitryx Therapeutics Ltd. Focuses on regulating cell metabolism to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation. It treats cancer and inflammatory conditions by targeting the metabolism of immune cells. The company was founded by Houman Ashrafian, Paul-Peter Tak, Luke O'Neill, Jonathan Powell, Jeff Rathmell and Michael Rosenblum and is headquartered in London, the United Kingdom.